Evidence map›Paper›PMID 30100722›Full record

ArticleInternational journal of nanomedicine2018

Rho GTPases in A549 and Caco-2 cells dominating the endocytic pathways of nanocarbons with different morphologies.

Siyang Song, Hongzhe Fu, Bing He, Dan Wang, Mengmeng Qin, Dan Yang, Dechun Liu, Ge Song, Yujie Shi, Hua Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Toxicology reports · 2022
    Article
  5. Article
  6. Carbon Nanotubes: Smart Drug/Gene Delivery Carriers.International journal of nanomedicine · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Siyang Song *School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Hongzhe Fu *Beijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Bing HeBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Dan WangPharmaceutics Department, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Mengmeng QinBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Dan YangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Dechun LiuBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Ge SongBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Yujie ShiBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Hua ZhangBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Xueqing WangBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Wenbing DaiBeijing Key Laboratory of Molecular Pharmaceutics and the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.
Qiang ZhangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China, daiwb@bjmu.edu.cn; zqdodo@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEndocytosis of nanomaterials is the first step of nano-bio interaction and current regulation is mostly by nanomaterials but seldom by intracellular signaling proteins. MATERIALS AND

methodsHerein, we synthesized tubular nanocarbon (oxMWCNT) and lamellar-like nanocarbon (oxGRAPHENE) and formulated their aqueous dispersion. A549 and Caco-2 cells were selected as the models of tumor and intestinal epithelial cells, respectively. After knocking down three members of Rho GTPases (Cdc42, Rac1, RhoA) in these two cell lines, their silencing effects on the uptake pathways of nanomaterials with different morphologies were investigated.

resultsAn unexpected finding was that the knock-down led to opposite uptake trends in different types of cells. The endocytosis of carbon nanomaterials increased in Caco-2 cells when Rho GTPases were inactivated, while that in A549 cells decreased. For nanomaterials with different shapes, the involved GTPase member of Rho family, or regulating protein molecule, was different. Concretely, Cdc42 and Rac1 were involved in oxMWCNT endocytosis, while all three GTPases participated in oxGRAPHENE internalization. More interestingly, such difference induced different uptake pathways, namely, the cellular uptake of oxMWCNT was clathrin-mediated and oxGRAPHENE was caveolin-modulated, both with the involvement of dynamin.

conclusionIn conclusion, this study provides new insights for the potential intervention in nano-bio interplay.

Indexed as

EndocytosisA549 CellsAnimalsBiological TransportCaco-2 CellsCarboncdc42 GTP-Binding ProteinCell SurvivalEpithelial CellsGraphiteHumansNanoparticlesNanotubes, CarbonOxidation-Reductionrac1 GTP-Binding ProteinrhoA GTP-Binding ProteinCarboncdc42 GTP-Binding ProteinGraphiteNanotubes, Carbonrac1 GTP-Binding ProteinrhoA GTP-Binding Proteinrho GTP-Binding Proteinscellular uptakeintracellular distributionnanomaterialsRho GTPasesshape

Identifiers

PMID30100722
PMCPMC6067611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.